PMID- 22797815
OWN - NLM
STAT- MEDLINE
DCOM- 20130524
LR  - 20211021
IS  - 1573-2592 (Electronic)
IS  - 0271-9142 (Print)
IS  - 0271-9142 (Linking)
VI  - 32
IP  - 6
DP  - 2012 Dec
TI  - HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B 
      recognized by CD4+ T-cell clones from chronically infected individuals.
PG  - 1305-16
LID - 10.1007/s10875-012-9732-x [doi]
AB  - PURPOSE: Helper CD4(+) T cells presumably play a major role in controlling 
      cytomegalovirus (CMV) by providing help to specific B and CD8(+) cytotoxic T 
      cells, as well as through cytotoxicity-mediated mechanisms. Since CMV 
      glycoprotein B (gB) is a major candidate for a subunit vaccine against CMV, we 
      searched for gB-epitopes presented by human leukocyte antigen (HLA)-class II 
      molecules. METHODS: Dendritic cells obtained from CMV-seropositive donors were 
      loaded with a recombinant gB and co-cultured with autologous CD4(+) T cells. 
      Microcultures that specifically recognized gB were cloned by limiting dilution 
      using autologous Epstein-Barr virus (EBV)-immortalized B cells pulsed with gB as 
      antigen-presenting cells. To pinpoint precisely the region encoding the natural 
      epitope recognized by a given CD4(+) clone, we assessed the recognition of 
      recombinant Escherichia coli expressing gB-overlapping polypeptides after their 
      processing by autologous EBV-B cells. RESULTS: We isolated several gB-specific 
      CD4(+) T-cell clones directed against peptides gB(190-204), gB(396-410), 
      gB(22-36) and gB(598-617) presented by HLA-DR7, HLA-DP10 and HLA-DP2. While their 
      precise role in controlling CMV infection remains to be established, gB-specific 
      CD4(+) T cells are likely to act by directly targeting infected HLA-class II 
      cells in vivo, as suggested by their recognition of EBV-B cells infected by the 
      Towne CMV strain. CONCLUSIONS: The characterization of such gB-epitopes presented 
      by HLA-class II should help to understand the contribution of CD4(+) T-cell 
      responses to CMV and may be of importance both in designing a vaccine against CMV 
      infection and in immunomonitoring of subjects immunized with recombinant gB or 
      with vectors encoding gB.
FAU - Ventura, Claire
AU  - Ventura C
AD  - Discovery Department, Sanofi Pasteur, 1541 Avenue Marcel Merieux, 69280 Marcy 
      l'Etoile, France.
FAU - Bisceglia, Helene
AU  - Bisceglia H
FAU - Girerd-Chambaz, Yves
AU  - Girerd-Chambaz Y
FAU - Burdin, Nicolas
AU  - Burdin N
FAU - Chaux, Pascal
AU  - Chaux P
LA  - eng
PT  - Journal Article
DEP - 20120715
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Epitopes)
RN  - 0 (HLA-DP Antigens)
RN  - 0 (HLA-DR7 Antigen)
RN  - 0 (Oligopeptides)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Viral Envelope Proteins)
RN  - 0 (glycoprotein B, Simplexvirus)
SB  - IM
MH  - Amino Acid Sequence
MH  - Antigen Presentation
MH  - B-Lymphocytes/immunology/pathology/virology
MH  - CD4-Positive T-Lymphocytes/*immunology/pathology/*virology
MH  - CD8-Positive T-Lymphocytes/immunology/pathology/virology
MH  - Chronic Disease
MH  - Clone Cells
MH  - Coculture Techniques
MH  - Cytomegalovirus/chemistry/*immunology/isolation & purification
MH  - Cytomegalovirus Infections/genetics/*immunology/pathology/virology
MH  - Dendritic Cells/immunology/pathology/virology
MH  - Epitopes/genetics/*immunology
MH  - Escherichia coli/genetics
MH  - HLA-DP Antigens/genetics/*immunology
MH  - HLA-DR7 Antigen/genetics/*immunology
MH  - Herpesvirus 4, Human/genetics/immunology
MH  - Humans
MH  - Molecular Sequence Data
MH  - Oligopeptides/genetics/immunology
MH  - Primary Cell Culture
MH  - Recombinant Proteins/genetics/immunology
MH  - T-Lymphocytes, Cytotoxic/immunology/pathology/virology
MH  - Viral Envelope Proteins/genetics/*immunology
PMC - PMC3528953
EDAT- 2012/07/17 06:00
MHDA- 2013/05/28 06:00
PMCR- 2012/07/15
CRDT- 2012/07/17 06:00
PHST- 2012/04/02 00:00 [received]
PHST- 2012/06/21 00:00 [accepted]
PHST- 2012/07/17 06:00 [entrez]
PHST- 2012/07/17 06:00 [pubmed]
PHST- 2013/05/28 06:00 [medline]
PHST- 2012/07/15 00:00 [pmc-release]
AID - 9732 [pii]
AID - 10.1007/s10875-012-9732-x [doi]
PST - ppublish
SO  - J Clin Immunol. 2012 Dec;32(6):1305-16. doi: 10.1007/s10875-012-9732-x. Epub 2012 
      Jul 15.